Clinical trial
Vasodilators and Anti-Oxidant Therapy in Early ATN
NCT00286403 · Southeast Renal Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00286403 |
|---|---|
| Title | Vasodilators and Anti-Oxidant Therapy in Early ATN |
| Official title | Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial |
| Lead sponsor | Southeast Renal Research Institute, Other |
| Collaborators | Dialysis Clinic, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Acute Renal Failure |
| Intervention type | Drug |
| Interventions | Fenoldopam Mesylate and/or MESNA |
| Enrollment | 0 |
| Start date | Aug 1, 2008 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Feb 3, 2006 |
| Last update posted | Mar 28, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: